{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"460","upperLimit":"582","value":"518"},{"groupId":"OG001","lowerLimit":"443","upperLimit":"673","value":"519"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"PFS was defined as the time between randomization and either disease progression or death, whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG000","title":"Part 2: VMP (Velcade+Melphalan+Prednisone)"},{"description":"Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG001","title":"Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) population: all randomized participants.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until disease progression or death, whichever occurred first, as assessed up to the last efficacy assessment for disease progression (approximately 3 years)","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Days"}